Edwards Lifesciences Stock Price, News & Analysis (NYSE:EW)

$133.82 -0.86 (-0.64 %)
(As of 02/18/2018 12:59 PM ET)
Previous Close$133.82
Today's Range$133.38 - $135.33
52-Week Range$89.20 - $138.48
Volume894,700 shs
Average Volume1.36 million shs
Market Capitalization$28.32 billion
P/E Ratio46.47
Dividend YieldN/A
Beta0.63

About Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences logoEdwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNYSE:EW
CUSIP28176E10
Phone+1-949-2502500

Debt

Debt-to-Equity Ratio0.15%
Current Ratio1.81%
Quick Ratio1.41%

Price-To-Earnings

Trailing P/E Ratio46.4652777777778
Forward P/E Ratio29.80
P/E Growth1.98

Sales & Book Value

Annual Sales$3.44 billion
Price / Sales8.24
Cash Flow$3.24 per share
Price / Cash41.34
Book Value$14.15 per share
Price / Book9.46

Profitability

Trailing EPS$2.88
Net Income$622.10 million
Net Margins18.11%
Return on Equity27.69%
Return on Assets15.54%

Miscellaneous

Employees11,100
Outstanding Shares211,620,000

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences shares split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were payable to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How will Edwards Lifesciences' stock buyback program work?

Edwards Lifesciences announced that its Board of Directors has initiated a share repurchase program on Thursday, December 7th 2017, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board believes its stock is undervalued.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) posted its earnings results on Thursday, February, 1st. The medical research company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.91 by $0.03. The medical research company had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The firm's quarterly revenue was up 15.7% on a year-over-year basis. During the same period last year, the firm earned $0.75 earnings per share. View Edwards Lifesciences' Earnings History.

When will Edwards Lifesciences make its next earnings announcement?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Edwards Lifesciences.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $4.43-4.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.27. The company issued revenue guidance of $3.5-3.9 billion, compared to the consensus revenue estimate of $3.74 billion.Edwards Lifesciences also updated its Q1 guidance to $1.04-1.14 EPS.

Where is Edwards Lifesciences' stock going? Where will Edwards Lifesciences' stock price be in 2018?

18 brokerages have issued 1 year price objectives for Edwards Lifesciences' stock. Their forecasts range from $105.00 to $174.00. On average, they expect Edwards Lifesciences' stock price to reach $141.94 in the next year. View Analyst Ratings for Edwards Lifesciences.

What are Wall Street analysts saying about Edwards Lifesciences stock?

Here are some recent quotes from research analysts about Edwards Lifesciences stock:

  • 1. According to Zacks Investment Research, "Edwards Lifesciences exited the fourth quarter 2017 on a solid note. The company has witnessed growth across all segments. It also performed well on both the gross and operating margin fronts. Also, the raised 2018 revenue and earnings guidance buoys optimism. We are currently looking forward to the company’s buyout of Harpoon Medical which should significantly boost its Surgical Heart Valve Therapy portfolio. Management expects to gain traction in the ever-expanding TAVR market, based on increasing preference in favor of transcatheter aortic valve replacement as well as compelling clinical evidence, leading to strong adoption of THV therapy. However, tough competition in the cardiac devices market and reimbursement issues continue to pose challenges. Also, over the past six months, Edwards Lifesciences has underperformed the broader industry." (2/8/2018)
  • 2. Cowen Inc analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)
  • 3. Evercore ISI analysts commented, "With lowered investor expectations, we believe EW shares are poised for a 'catch-up' trade and offers asymmetric risk-reward at current levels. As a result, we are upgrading shares to a Buy, and raising our PT to $110, which offers ~15% upside from current levels." (3/27/2017)

Who are some of Edwards Lifesciences' key competitors?

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:

  • Michael A. Mussallem, Chairman of the Board, Chief Executive Officer (Age 64)
  • Scott B. Ullem, Chief Financial Officer, Corporate Vice President (Age 51)
  • Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy (Age 55)
  • Catherine M. Szyman, Corporate Vice President- Critical Care (Age 50)
  • Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa (Age 59)
  • Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific (Age 60)
  • Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy (Age 51)
  • Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy (Age 49)
  • Kieran T. Gallahue, Independent Director (Age 53)
  • Leslie Stone Heisz, Independent Director (Age 56)

Who owns Edwards Lifesciences stock?

Edwards Lifesciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.28%), Bank of New York Mellon Corp (3.58%), Sands Capital Management LLC (3.29%), Alliancebernstein L.P. (2.96%), Brown Advisory Inc. (1.77%) and Geode Capital Management LLC (1.14%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Steven R Loranger and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

Who sold Edwards Lifesciences stock? Who is selling Edwards Lifesciences stock?

Edwards Lifesciences' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jennison Associates LLC, Old Mutual Global Investors UK Ltd., Arrowstreet Capital Limited Partnership, Sands Capital Management LLC, Quantitative Investment Management LLC, Wells Fargo & Company MN and American Century Companies Inc.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

Who bought Edwards Lifesciences stock? Who is buying Edwards Lifesciences stock?

Edwards Lifesciences' stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Two Sigma Advisers LP, Alliancebernstein L.P., Two Sigma Investments LP, Champlain Investment Partners LLC, Winslow Capital Management LLC, Amundi Pioneer Asset Management Inc. and BlackRock Inc.. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue and Steven R Loranger. View Insider Buying and Selling for Edwards Lifesciences.

How do I buy Edwards Lifesciences stock?

Shares of Edwards Lifesciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of Edwards Lifesciences stock can currently be purchased for approximately $133.82.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $28.32 billion and generates $3.44 billion in revenue each year. The medical research company earns $622.10 million in net income (profit) each year or $2.88 on an earnings per share basis. Edwards Lifesciences employs 11,100 workers across the globe.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is 1 Edwards Way, IRVINE, CA 92614-5688, United States. The medical research company can be reached via phone at +1-949-2502500 or via email at [email protected]


MarketBeat Community Rating for Edwards Lifesciences (EW)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  836 (Vote Outperform)
Underperform Votes:  600 (Vote Underperform)
Total Votes:  1,436
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Edwards Lifesciences (NYSE:EW) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.942.842.812.79
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $141.94$129.87$124.95$119.39
Price Target Upside: 7.39% upside13.33% upside20.92% upside3.36% upside

Edwards Lifesciences (NYSE:EW) Consensus Price Target History

Price Target History for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE:EW) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018GuggenheimReiterated RatingBuy$162.00LowView Rating Details
2/2/2018JMP SecuritiesBoost Price TargetMarket Outperform -> Market Outperform$135.00 -> $140.00HighView Rating Details
2/2/2018Stifel NicolausReiterated RatingBuy$155.00HighView Rating Details
2/2/2018BarclaysBoost Price TargetOverweight -> Overweight$135.00 -> $155.00HighView Rating Details
2/2/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$130.00 -> $138.00HighView Rating Details
2/2/2018Canaccord GenuityReiterated RatingBuy -> Buy$140.00 -> $174.00HighView Rating Details
2/1/2018CowenReiterated RatingBuy$150.00HighView Rating Details
1/31/2018SunTrust BanksReiterated RatingBuy$150.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform -> Outperform$140.00HighView Rating Details
1/2/2018JPMorgan Chase & Co.DowngradeOverweight -> NeutralMediumView Rating Details
12/8/2017BMO Capital MarketsReiterated RatingBuy$137.00LowView Rating Details
10/26/2017Deutsche BankLower Price TargetHold$122.00 -> $115.00N/AView Rating Details
9/1/2017Royal Bank of CanadaReiterated RatingBuy$130.00N/AView Rating Details
8/28/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
7/27/2017Bank of AmericaBoost Price TargetPositive -> Buy$140.00 -> $150.00HighView Rating Details
7/27/2017Jefferies GroupBoost Price TargetBuy$115.00 -> $132.00HighView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageConviction-Buy$138.00LowView Rating Details
3/20/2017Northland SecuritiesSet Price TargetBuy$105.00LowView Rating Details
2/8/2017Credit Suisse GroupSet Price TargetBuy$120.00N/AView Rating Details
2/2/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
2/2/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
7/27/2016CitigroupBoost Price TargetSell$86.00 -> $94.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$123.00N/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$101.00N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Edwards Lifesciences (NYSE:EW) Earnings History and Estimates Chart

Earnings by Quarter for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE EW) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/23/2018$1.04N/AView Earnings Details
2/1/2018Q4 2017$0.91$0.94$868.45 million$888.50 millionViewListenView Earnings Details
10/24/2017Q3 2017$0.86$0.84$833.85 million$821.50 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.88$1.08$839.16 million$842.00 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.82$0.94$776.51 million$883.50 millionViewN/AView Earnings Details
2/1/2017Q416$0.72$0.75$760.85 million$767.70 millionViewN/AView Earnings Details
10/25/2016Q316$0.68$0.68$749.14 million$739.40 millionViewN/AView Earnings Details
7/26/2016Q216$0.70$0.76$724.26 million$759.30 millionViewN/AView Earnings Details
4/26/2016Q116$0.66$0.71$664.53 million$697.30 millionViewN/AView Earnings Details
2/2/2016Q415$0.62$0.63$647.44 million$671.10 millionViewN/AView Earnings Details
10/26/2015Q315$0.98$1.07$598.29 million$615.00 millionViewN/AView Earnings Details
7/28/2015Q215$1.05$1.13$604.97 million$616.80 millionViewN/AView Earnings Details
4/23/2015Q115$1.04$1.12$585.16 million$590.30 millionViewN/AView Earnings Details
2/3/2015Q414$0.95$1.06$610.50 million$618.00 millionViewListenView Earnings Details
10/23/2014Q314$0.72$0.80$546.10 million$607.40 millionViewListenView Earnings Details
7/29/2014Q214$0.77$0.88$545.10 million$547.00 millionViewListenView Earnings Details
4/24/2014Q114$0.69$0.76$523.10 million$522.40 millionViewListenView Earnings Details
2/3/2014Q413$0.82$0.91$533.82 million$536.00 millionViewN/AView Earnings Details
10/28/2013Q313$0.66$0.68$490.96 million$496.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013$0.76$0.82$514.59 million$517.20 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.76$0.72$518.69 million$496.70 millionViewN/AView Earnings Details
2/4/2013Q4 2012$0.77$0.77$499.46 million$510.50 millionViewN/AView Earnings Details
10/19/2012$0.56$0.58ViewN/AView Earnings Details
7/24/2012$0.66$0.67ViewN/AView Earnings Details
4/24/2012Q1 2012$0.24$0.27ViewN/AView Earnings Details
2/2/2012$0.59$0.62ViewN/AView Earnings Details
10/19/2011$0.39$0.38ViewN/AView Earnings Details
7/21/2011$0.50$0.49ViewN/AView Earnings Details
4/20/2011$0.42$0.51ViewN/AView Earnings Details
2/2/2011$0.53$0.55ViewN/AView Earnings Details
10/25/2010Q3 2010$0.21$0.21ViewN/AView Earnings Details
7/21/2010Q2 2010$0.22$0.23ViewN/AView Earnings Details
4/20/2010Q1 2010$0.20$0.20ViewN/AView Earnings Details
2/4/2010Q4 2009$0.21$0.21ViewN/AView Earnings Details
10/21/2009Q3 2009$0.18$0.18ViewN/AView Earnings Details
7/20/2009Q2 2009$0.19$0.20ViewN/AView Earnings Details
4/27/2009Q1 2009$0.17$0.18ViewN/AView Earnings Details
2/3/2009Q4 2008$0.19$0.19ViewN/AView Earnings Details
10/21/2008Q3 2008$0.14$0.14ViewN/AView Earnings Details
7/22/2008Q2 2008$0.16$0.16ViewN/AView Earnings Details
4/22/2008Q1 2008$0.12$0.14ViewN/AView Earnings Details
2/5/2008Q4 2007$0.13$0.14ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Edwards Lifesciences (NYSE:EW) Earnings Estimates

2018 EPS Consensus Estimate: $4.47
2019 EPS Consensus Estimate: $4.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.98$1.13$1.08
Q2 20184$1.14$1.22$1.17
Q3 20184$1.04$1.13$1.08
Q4 20184$1.08$1.22$1.14
Q1 20191$1.24$1.24$1.24
Q2 20192$1.28$1.28$1.28
Q3 20192$1.19$1.22$1.21
Q4 20191$1.26$1.26$1.26
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Edwards Lifesciences (NYSE:EW)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Edwards Lifesciences (NYSE EW) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 81.11%
Insider Trades by Quarter for Edwards Lifesciences (NYSE:EW)
Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE EW) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Michael A MussallemCEOSell32,800$126.69$4,155,432.0074,131View SEC Filing  
2/12/2018Donald E Bobo JrVPSell3,750$127.54$478,275.0019,608View SEC Filing  
2/9/2018William J Phd LinkDirectorSell12,000$122.24$1,466,880.0024,596View SEC Filing  
2/5/2018Robert W.A. SellersVPSell12,020$131.03$1,574,980.60View SEC Filing  
1/29/2018Donald E Bobo JrVPSell5,300$127.24$674,372.0024,908View SEC Filing  
1/16/2018Larry L WoodVPSell6,300$121.00$762,300.00116,148View SEC Filing  
1/4/2018Michael A. MussallemCEOSell32,800$114.97$3,771,016.00View SEC Filing  
12/28/2017Donald E. Bobo, Jr.VPSell5,300$114.08$604,624.00View SEC Filing  
12/28/2017Donald E. Bobo, Jr.VPSell5,300$114.08$604,624.00View SEC Filing  
12/19/2017Michael A. MussallemCEOSell32,800$114.82$3,766,096.00View SEC Filing  
12/15/2017Larry L. WoodVPSell18,960$114.58$2,172,436.80View SEC Filing  
11/29/2017Donald E. Bobo, Jr.VPSell5,300$116.45$617,185.00View SEC Filing  
11/20/2017Michael A. MussallemCEOSell32,900$106.86$3,515,694.00View SEC Filing  
11/15/2017Larry L. WoodVPSell18,960$104.76$1,986,249.60View SEC Filing  
11/9/2017Schack Wesley W VonDirectorSell1,000$104.15$104,150.002,622View SEC Filing  
10/30/2017Donald E. Bobo, Jr.VPSell5,300$101.12$535,936.00View SEC Filing  
10/30/2017Michael A. MussallemCEOSell32,900$100.93$3,320,597.00View SEC Filing  
10/16/2017Larry L WoodVPSell18,960$108.54$2,057,918.40View SEC Filing  
9/29/2017Donald E. Bobo, Jr.VPSell5,300$108.86$576,958.00View SEC Filing  
9/15/2017Larry L. WoodVPSell18,960$112.58$2,134,516.80View SEC Filing  
9/7/2017Michael A. MussallemCEOSell32,900$112.45$3,699,605.00View SEC Filing  
8/30/2017Larry L. WoodVPSell18,960$111.81$2,119,917.60View SEC Filing  
8/29/2017Donald E. Bobo, Jr.VPSell5,300$112.15$594,395.00View SEC Filing  
8/9/2017Michael A. MussallemCEOSell32,900$115.99$3,816,071.00View SEC Filing  
8/4/2017Donald E. Bobo, Jr.VPSell25,000$116.00$2,900,000.00View SEC Filing  
7/31/2017Catherine M. SzymanVPSell4,681$115.78$541,966.18View SEC Filing  
7/31/2017Michael A. MussallemCEOSell32,900$114.80$3,776,920.00View SEC Filing  
7/28/2017Donald E. Bobo, Jr.VPSell5,300$114.68$607,804.00View SEC Filing  
6/29/2017Donald E. Bobo, Jr.VPSell5,600$117.15$656,040.00View SEC Filing  
6/7/2017Michael A. MussallemCEOSell32,900$118.05$3,883,845.00View SEC Filing  
5/31/2017Patrick B. VerguetVPSell10,000$114.88$1,148,800.00View SEC Filing  
5/19/2017Dylan SidooDirectorBuy25,000$0.11$2,750.00
5/19/2017Patrick B. VerguetVPSell22,631$113.16$2,560,923.96View SEC Filing  
5/15/2017Patrick B. VerguetVPSell11,500$111.64$1,283,860.00View SEC Filing  
5/8/2017Donald E. Bobo, Jr.VPSell19,100$110.34$2,107,494.00View SEC Filing  
5/4/2017Donald E. Bobo, Jr.VPSell34,120$109.98$3,752,517.60View SEC Filing  
5/3/2017Michael A. MussallemCEOSell49,100$109.71$5,386,761.00View SEC Filing  
4/28/2017Michael A. MussallemCEOSell49,100$109.78$5,390,198.00View SEC Filing  
4/27/2017Bernard J. ZovighianVPSell18,050$109.21$1,971,240.50View SEC Filing  
4/5/2017Donald E. Bobo, Jr.VPSell13,720$93.58$1,283,917.60View SEC Filing  
3/30/2017Patrick B. VerguetVPSell24,000$93.90$2,253,600.00View SEC Filing  
3/6/2017Donald E. Bobo, Jr.VPSell13,720$90.01$1,234,937.20View SEC Filing  
2/16/2017Michael A. MussallemCEOSell49,100$89.63$4,400,833.00View SEC Filing  
2/3/2017Kieran GallahueDirectorBuy3,000$90.10$270,300.002,524View SEC Filing  
1/13/2017Michael A. MussallemCEOSell49,100$97.08$4,766,628.00View SEC Filing  
1/12/2017Donald E. Bobo, Jr.VPSell13,720$97.47$1,337,288.40View SEC Filing  
1/12/2017Dylan SidooDirectorBuy30,000$0.13$3,900.00
1/11/2017Dylan SidooDirectorBuy20,000$0.13$2,600.00
12/19/2016Michael A. MussallemCEOSell49,100$91.96$4,515,236.00View SEC Filing  
12/5/2016Huimin WangVPSell13,650$83.53$1,140,184.50View SEC Filing  
12/1/2016Larry L. WoodVPSell13,258$81.85$1,085,167.30View SEC Filing  
11/30/2016Catherine M. SzymanVPBuy12,870$83.43$1,073,744.10View SEC Filing  
11/29/2016Kieran GallahueDirectorBuy3,000$84.63$253,890.00View SEC Filing  
11/22/2016Michael A. MussallemCEOSell49,100$84.67$4,157,297.00View SEC Filing  
11/7/2016Huimin WangVPSell13,650$91.29$1,246,108.50View SEC Filing  
11/2/2016Donald E. Bobo, Jr.VPSell15,000$90.13$1,351,950.00View SEC Filing  
11/1/2016Larry L. WoodVPSell13,257$93.27$1,236,480.39View SEC Filing  
10/27/2016Michael A. MussallemCEOSell49,100$92.77$4,555,007.00View SEC Filing  
10/5/2016Huimin WangVPSell13,650$120.04$1,638,546.00View SEC Filing  
10/3/2016Larry L. WoodVPSell13,257$119.27$1,581,162.39View SEC Filing  
9/6/2016Huimin WangVPSell13,650$115.72$1,579,578.00View SEC Filing  
9/2/2016Donald E. Bobo, Jr.VPSell18,000$115.78$2,084,040.00View SEC Filing  
8/26/2016Patrick B. VerguetVPSell5,000$114.88$574,400.00View SEC Filing  
8/24/2016Patrick B. VerguetVPSell5,000$116.81$584,050.00View SEC Filing  
8/23/2016Patrick B. VerguetVPSell10,092$117.53$1,186,112.76View SEC Filing  
8/11/2016Michael A. MussallemCEOSell49,100$114.01$5,597,891.00View SEC Filing  
8/10/2016John T. CardisDirectorSell5,000$113.21$566,050.00View SEC Filing  
8/9/2016Patrick B. VerguetVPSell10,000$113.48$1,134,800.00View SEC Filing  
8/5/2016Huimin WangVPSell13,650$113.03$1,542,859.50View SEC Filing  
8/1/2016Larry L. WoodVPSell13,257$114.24$1,514,479.68View SEC Filing  
8/1/2016Schack Wesley W. VonDirectorSell6,000$113.98$683,880.00View SEC Filing  
7/29/2016Robert W.A. SellersVPSell10,000$114.33$1,143,300.00View SEC Filing  
7/28/2016Michael A. MussallemCEOSell49,100$113.31$5,563,521.00View SEC Filing  
7/5/2016Huimin WangVPSell13,650$98.44$1,343,706.00View SEC Filing  
7/1/2016Larry L. WoodVPSell13,257$98.79$1,309,659.03View SEC Filing  
6/8/2016Michael A MussallemCEOSell49,100$102.75$5,045,025.00127,341View SEC Filing  
6/6/2016Huimin WangVPSell13,650$101.34$1,383,291.0089,272View SEC Filing  
6/3/2016Larry L WoodVPSell13,257$101.38$1,343,994.66115,083View SEC Filing  
5/31/2016Donald E Bobo JrVPSell18,000$99.04$1,782,720.0062,796View SEC Filing  
5/24/2016Steven R LorangerDirectorBuy5,000$101.07$505,350.001,941View SEC Filing  
5/18/2016Patrick B VerguetVPSell13,000$102.75$1,335,750.00129,944View SEC Filing  
5/17/2016Patrick B VerguetVPSell5,000$105.00$525,000.00129,944View SEC Filing  
5/16/2016Patrick B VerguetVPSell3,000$104.62$313,860.00129,944View SEC Filing  
5/5/2016Huimin WangVPSell13,650$103.36$1,410,864.0081,480View SEC Filing  
5/5/2016Michael A MussallemCEOSell59,000$104.12$6,143,080.0068,256View SEC Filing  
5/2/2016Patrick B VerguetVPSell7,000$106.86$748,020.00115,107View SEC Filing  
4/29/2016Michael A MussallemCEOSell59,000$106.13$6,261,670.0079,256View SEC Filing  
4/5/2016Huimin WangVPSell13,650$103.97$1,419,190.5081,480View SEC Filing  
3/17/2016Michael A MussallemCEOSell59,000$84.39$4,979,010.0080,650View SEC Filing  
3/7/2016Huimin WangVPSell13,650$87.17$1,189,870.5081,299View SEC Filing  
2/18/2016Michael A. MussallemCEOSell59,000$86.94$5,129,460.00View SEC Filing  
2/18/2016Patrick B. VerguetVPSell5,000$87.00$435,000.00View SEC Filing  
2/16/2016Patrick B. VerguetVPSell8,000$81.58$652,640.00View SEC Filing  
2/5/2016Huimin WangVPSell13,650$83.46$1,139,229.00View SEC Filing  
2/4/2016Barbara J. McneilDirectorSell4,000$83.29$333,160.00View SEC Filing  
1/21/2016Patrick B. VerguetVPSell8,000$77.00$616,000.0099,803View SEC Filing  
1/6/2016Nick DemareDirectorBuy15,000$0.08$1,200.00
1/5/2016Huimin WangVPSell13,650$78.50$1,071,525.0067,649View SEC Filing  
1/5/2016Michael A. MussallemCEOSell59,000$79.82$4,709,380.0021,650View SEC Filing  
12/17/2015Michael A. MussallemCEOSell59,000$81.85$4,829,150.0021,650View SEC Filing  
12/15/2015Patrick B. VerguetVPSell8,000$80.87$646,960.0099,803View SEC Filing  
12/4/2015Huimin WangVPSell6,880$157.96$1,086,764.8033,824View SEC Filing  
11/27/2015Patrick B. VerguetVPSell7,500$164.50$1,233,750.0049,901View SEC Filing  
11/23/2015Robert W.A. SellersVPSell19,200$157.13$3,016,896.0013,158View SEC Filing  
11/17/2015Patrick B. VerguetVPSell4,000$154.50$618,000.0049,901View SEC Filing  
11/5/2015Huimin WangVPSell6,920$156.01$1,079,589.2034,174View SEC Filing  
11/3/2015Patrick B. VerguetVPSell4,338$158.48$687,486.2449,901View SEC Filing  
10/30/2015Patrick B. VerguetVPSell22,000$155.09$3,411,980.0049,901View SEC Filing  
10/29/2015Michael A MussallemCEOSell29,500$154.59$4,560,405.0040,325View SEC Filing  
10/5/2015Huimin WangVPSell6,920$154.30$1,067,756.0034,174View SEC Filing  
10/2/2015Patrick B. VerguetVPSell4,000$154.00$616,000.0053,901View SEC Filing  
10/1/2015Larry L. WoodVPSell7,680$141.52$1,086,873.6043,838View SEC Filing  
9/21/2015Michael A. MussallemCEOSell29,500$142.49$4,203,455.0010,825View SEC Filing  
9/4/2015Huimin WangVPSell6,920$135.19$935,514.8034,174View SEC Filing  
9/1/2015Larry L. WoodVPSell7,680$137.50$1,056,000.0043,838View SEC Filing  
8/24/2015Michael A. MussallemCEOSell29,500$135.25$3,989,875.00279,887View SEC Filing  
8/13/2015West Petroleum Corp. EastInsiderBuy25,000$0.12$2,875.00
7/6/2015Huimin WangVPSell6,920$143.95$996,134.00View SEC Filing  
7/1/2015Larry L WoodVPSell7,680$143.51$1,102,156.80View SEC Filing  
6/24/2015Michael A MussallemCEOSell29,500$143.71$4,239,445.00View SEC Filing  
6/5/2015Huimin WangVPSell6,920$131.39$909,218.80View SEC Filing  
6/1/2015Larry L WoodVPSell7,680$130.47$1,002,009.60View SEC Filing  
5/29/2015Patrick B VerguetVPSell9,662$131.18$1,267,461.16View SEC Filing  
5/21/2015Barbara J McneilDirectorSell2,000$132.59$265,180.00View SEC Filing  
5/19/2015Robert Marc BustinDirectorSell10,000$0.18$1,750.00
5/1/2015Larry L WoodVPSell7,680$127.12$976,281.60View SEC Filing  
4/30/2015Michael A MussallemCEOSell29,500$128.99$3,805,205.00View SEC Filing  
4/6/2015Huimin WangVPSell6,920$140.24$970,460.80View SEC Filing  
4/1/2015Larry L WoodVPSell7,680$142.06$1,091,020.80View SEC Filing  
3/31/2015Robert Marc BustinDirectorBuy15,000$0.15$2,250.00
3/26/2015Michael A MussallemCEOSell29,500$140.10$4,132,950.00View SEC Filing  
3/2/2015Larry L WoodVPSell7,680$132.62$1,018,521.60View SEC Filing  
2/6/2015Huimin WangVPSell6,920$134.79$932,746.80View SEC Filing  
1/5/2015Huimin WangVPSell6,920$126.60$876,072.00View SEC Filing  
1/5/2015Michael A MussallemCEOSell29,500$128.20$3,781,900.00View SEC Filing  
12/22/2014Michael A MussallemCEOSell29,500$133.01$3,923,795.00View SEC Filing  
11/24/2014Michael A MussallemCEOSell29,500$124.25$3,665,375.00View SEC Filing  
11/13/2014Robert W.A. SellersVPSell3,400$124.27$422,518.00View SEC Filing  
11/10/2014Patrick B VerguetVPSell5,000$123.70$618,500.00View SEC Filing  
11/7/2014Schack Wesley W VonDirectorSell3,655$123.00$449,565.00View SEC Filing  
11/5/2014Huimin WangVPSell5,600$120.26$673,456.00View SEC Filing  
10/28/2014Barbara J McneilDirectorSell1,000$117.94$117,940.00View SEC Filing  
10/28/2014Michael A MussallemCEOSell29,500$117.06$3,453,270.00View SEC Filing  
10/28/2014Patrick B VerguetVPSell15,000$117.33$1,759,950.00View SEC Filing  
10/28/2014West Petroleum Corp. EastInsiderBuy15,000$0.12$1,800.00
10/27/2014Patrick B VerguetVPSell10,000$117.00$1,170,000.00View SEC Filing  
10/27/2014West Petroleum Corp. EastInsiderBuy20,000$0.13$2,600.00
10/24/2014Donald E Bobo JrVPSell30,000$114.25$3,427,500.00View SEC Filing  
10/24/2014West Petroleum Corp. EastInsiderBuy35,000$0.14$4,725.00
10/23/2014West Petroleum Corp. EastInsiderBuy40,000$0.15$5,800.00
10/6/2014Huimin WangVPSell5,600$107.00$599,200.00View SEC Filing  
10/3/2014Donald E Bobo JrVPSell25,000$105.00$2,625,000.00View SEC Filing  
9/29/2014Michael A MussallemCEOSell29,500$102.71$3,029,945.00View SEC Filing  
9/10/2014Donald E Bobo JrVPSell25,000$100.00$2,500,000.00View SEC Filing  
9/5/2014Huimin WangVPSell5,600$98.29$550,424.00View SEC Filing  
8/27/2014Carlyn D SolomonVPSell85,200$97.85$8,336,820.00View SEC Filing  
8/27/2014Michael A MussallemCEOSell29,500$98.14$2,895,130.00View SEC Filing  
8/18/2014John T CardisDirectorSell6,000$97.92$587,520.00View SEC Filing  
8/18/2014Larry L WoodVPSell63,752$97.85$6,238,133.20View SEC Filing  
8/13/2014Patrick B VerguetVPSell7,800$95.50$744,900.00View SEC Filing  
8/5/2014Patrick B VerguetVPSell15,000$94.05$1,410,750.00View SEC Filing  
8/4/2014Patrick B VerguetVPSell5,000$93.00$465,000.00View SEC Filing  
8/1/2014Patrick B VerguetVPSell5,000$92.00$460,000.00View SEC Filing  
7/31/2014Michael A MussallemCEOSell29,500$91.98$2,713,410.00View SEC Filing  
7/31/2014Robert Alexander IngramDirectorSell12,500$90.26$1,128,250.00View SEC Filing  
7/31/2014Robert W.A. SellersVPSell8,850$91.47$809,509.50View SEC Filing  
7/30/2014Donald E Bobo JrVPSell23,270$92.00$2,140,840.00View SEC Filing  
7/7/2014Huimin WangVPSell5,600$87.79$491,624.00View SEC Filing  
6/27/2014Donald E Bobo JrVPSell25,000$87.00$2,175,000.00View SEC Filing  
6/24/2014Michael A MussallemCEOSell29,500$85.38$2,518,710.00View SEC Filing  
6/5/2014Huimin WangVPSell5,600$80.73$452,088.00View SEC Filing  
5/30/2014Barbara J McneilDirectorSell1,200$81.20$97,440.00View SEC Filing  
5/28/2014Michael A MussallemCEOSell29,500$79.33$2,340,235.00View SEC Filing  
4/14/2014Donald Bobo, Jr.VPSell25,000$82.00$2,050,000.0020,604View SEC Filing  
4/10/2014Michael MussallemCEOSell29,500$74.71$2,203,945.00263,850View SEC Filing  
4/7/2014Huimin WangVPSell5,600$74.03$414,568.0031,549View SEC Filing  
3/24/2014Michael BowlinDirectorSell1,093$72.33$79,056.6977,199View SEC Filing  
3/6/2014Robert W.A. SellersVPSell1,650$72.88$120,252.0020,570View SEC Filing  
2/6/2014Michael MussallemCEOSell29,500$66.92$1,974,140.00263,850View SEC Filing  
1/27/2014Michael BowlinDirectorSell1,092$68.65$74,965.8077,199View SEC Filing  
1/9/2014Michael MussallemCEOSell29,500$67.04$1,977,680.00263,850View SEC Filing  
1/6/2014Huimin WangVPSell5,600$67.14$375,984.0031,337View SEC Filing  
12/11/2013Patrick VerguetVPSell10,000$62.34$623,400.0048,681View SEC Filing  
12/5/2013Huimin WangVPSell4,650$64.65$300,622.5031,337View SEC Filing  
12/4/2013Michael MussallemCEOSell29,500$64.90$1,914,550.00263,850View SEC Filing  
10/9/2013Michael MussallemCEOSell29,500$72.63$2,142,585.00263,850View SEC Filing  
10/4/2013Huimin WangVPSell4,850$72.19$350,121.5031,337View SEC Filing  
9/12/2013Michael MussallemCEOSell29,500$71.82$2,118,690.00263,850View SEC Filing  
9/5/2013Huimin WangVPSell4,850$71.24$345,514.0031,337View SEC Filing  
8/8/2013Michael MussallemCEOSell29,500$72.28$2,132,260.00263,850View SEC Filing  
8/5/2013Huimin WangVPSell4,850$72.30$350,655.0031,337View SEC Filing  
8/1/2013Patrick VerguetVPSell20,000$73.15$1,463,000.0048,681View SEC Filing  
7/10/2013Michael A MussallemCEOSell29,500$65.60$1,935,200.00View SEC Filing  
7/5/2013Huimin WangVPSell4,850$65.69$318,596.50View SEC Filing  
6/6/2013Michael A MussallemCEOSell29,500$66.25$1,954,375.00View SEC Filing  
6/5/2013Huimin WangVPSell4,850$65.11$315,783.50View SEC Filing  
5/13/2013Paul C RedmondVPSell5,000$67.35$336,750.00View SEC Filing  
5/8/2013Michael A MussallemCEOSell29,200$64.24$1,875,808.00View SEC Filing  
5/7/2013Thomas M AbateCFOSell15,000$63.75$956,250.00View SEC Filing  
5/3/2013Schack Wesley W VonDirectorBuy1,000$64.00$64,000.00View SEC Filing  
5/1/2013David E I PyottDirectorBuy3,000$62.95$188,850.00View SEC Filing  
5/1/2013John H Kehl JrVPSell12,500$62.72$784,000.00View SEC Filing  
4/26/2013Schack Wesley W VonDirectorBuy2,000$64.95$129,900.00View SEC Filing  
4/10/2013Michael A MussallemCEOSell35,000$83.37$2,917,950.00View SEC Filing  
3/13/2013John H Kehl JrVPSell12,500$87.75$1,096,875.00View SEC Filing  
10/5/2012Huimin WangVPSell6,250$109.88$686,750.00View SEC Filing  
10/4/2012Donald E Bobo JrVPSell11,530$110.14$1,269,914.20View SEC Filing  
8/9/2012Michael A MussallemCEOSell35,000$98.69$3,454,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Edwards Lifesciences (NYSE EW) News Headlines

Source:
DateHeadline
Edwards Lifesciences Corp (EW) Files 10-K for the Fiscal Year Ended on December 31, 2017Edwards Lifesciences Corp (EW) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 17 at 9:02 AM
 Brokerages Anticipate Edwards Lifesciences Corp (EW) Will Announce Earnings of $1.10 Per Share Brokerages Anticipate Edwards Lifesciences Corp (EW) Will Announce Earnings of $1.10 Per Share
www.americanbankingnews.com - February 17 at 3:04 AM
Edwards Lifesciences' CE Mark for CENTERA Boosts THVT ArmEdwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm
finance.yahoo.com - February 16 at 4:34 PM
Edwards Lifesciences CE Mark for CENTERA Boosts THVT ArmEdwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm
www.zacks.com - February 16 at 9:07 AM
Edwards Lifesciences (EW) Announces Self-Expanding Transcatheter Heart Valve Received CE MarkEdwards Lifesciences (EW) Announces Self-Expanding Transcatheter Heart Valve Received CE Mark
www.streetinsider.com - February 15 at 4:36 PM
Edwards Self-Expanding Transcatheter Heart Valve Receives CE MarkEdwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark
finance.yahoo.com - February 15 at 4:36 PM
Edwards Lifesciences Corp (EW) CEO Sells $4,155,432.00 in StockEdwards Lifesciences Corp (EW) CEO Sells $4,155,432.00 in Stock
www.americanbankingnews.com - February 13 at 9:12 PM
William J. Phd Link Sells 12,000 Shares of Edwards Lifesciences Corp (EW) StockWilliam J. Phd Link Sells 12,000 Shares of Edwards Lifesciences Corp (EW) Stock
www.americanbankingnews.com - February 13 at 9:10 PM
Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 3,750 Shares of StockInsider Selling: Edwards Lifesciences Corp (EW) VP Sells 3,750 Shares of Stock
www.americanbankingnews.com - February 13 at 9:10 PM
Brokers Offer Predictions for Edwards Lifesciences Corps Q1 2018 Earnings (EW)Brokers Offer Predictions for Edwards Lifesciences Corp's Q1 2018 Earnings (EW)
www.americanbankingnews.com - February 9 at 8:26 AM
Edwards Lifesciences (EW) Lifted to Buy at Zacks Investment ResearchEdwards Lifesciences (EW) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - February 8 at 1:46 PM
Three Large-Cap Healthcare Stocks You Must Buy Following the ... - TheStreet.comThree Large-Cap Healthcare Stocks You Must Buy Following the ... - TheStreet.com
www.thestreet.com - February 8 at 6:18 AM
3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback
finance.yahoo.com - February 8 at 6:18 AM
Robert W.A. Sellers Sells 12,020 Shares of Edwards Lifesciences Corp (EW) StockRobert W.A. Sellers Sells 12,020 Shares of Edwards Lifesciences Corp (EW) Stock
www.americanbankingnews.com - February 7 at 12:14 AM
William Blair Weighs in on Edwards Lifesciences Corps Q2 2018 Earnings (EW)William Blair Weighs in on Edwards Lifesciences Corp's Q2 2018 Earnings (EW)
www.americanbankingnews.com - February 5 at 3:34 AM
Leerink Swann Weighs in on Edwards Lifesciences Corps Q1 2018 Earnings (EW)Leerink Swann Weighs in on Edwards Lifesciences Corp's Q1 2018 Earnings (EW)
www.americanbankingnews.com - February 5 at 2:28 AM
Q1 2018 Earnings Forecast for Edwards Lifesciences Corp (EW) Issued By Jefferies GroupQ1 2018 Earnings Forecast for Edwards Lifesciences Corp (EW) Issued By Jefferies Group
www.americanbankingnews.com - February 5 at 2:28 AM
Edwards Lifesciences Corp (EW) Expected to Post FY2017 Earnings of $3.77 Per ShareEdwards Lifesciences Corp (EW) Expected to Post FY2017 Earnings of $3.77 Per Share
www.americanbankingnews.com - February 5 at 1:04 AM
Luna Innovations (LUNA) & Edwards Lifesciences (EW) Financial ContrastLuna Innovations (LUNA) & Edwards Lifesciences (EW) Financial Contrast
www.americanbankingnews.com - February 3 at 11:18 PM
Notable Friday Option Activity: BAC, MINI, EW - Nasdaq.com - NasdaqNotable Friday Option Activity: BAC, MINI, EW - Nasdaq.com - Nasdaq
www.nasdaq.com - February 3 at 6:25 AM
3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Edwards Lifesciences Corp (EW) and Motorola Solutions Inc (MSI) - Investorplace.com3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Edwards Lifesciences Corp (EW) and Motorola Solutions Inc (MSI) - Investorplace.com
investorplace.com - February 3 at 6:25 AM
Edwards Lifesciences Corp. Earnings Rise In Q4 - Nasdaq.com - NasdaqEdwards Lifesciences Corp. Earnings Rise In Q4 - Nasdaq.com - Nasdaq
www.nasdaq.com - February 3 at 6:25 AM
Markets Are Down, But These Stocks Surged to All-Time Highs TodayMarkets Are Down, But These Stocks Surged to All-Time Highs Today
finance.yahoo.com - February 3 at 6:25 AM
Barclays Boosts Edwards Lifesciences (EW) Price Target to $155.00Barclays Boosts Edwards Lifesciences (EW) Price Target to $155.00
www.americanbankingnews.com - February 2 at 10:24 PM
Edwards Lifesciences (EW) Price Target Raised to $138.00Edwards Lifesciences (EW) Price Target Raised to $138.00
www.americanbankingnews.com - February 2 at 10:24 PM
JMP Securities Boosts Edwards Lifesciences (EW) Price Target to $140.00JMP Securities Boosts Edwards Lifesciences (EW) Price Target to $140.00
www.americanbankingnews.com - February 2 at 5:36 PM
Edwards Lifesciences (EW) "Buy" Rating Reaffirmed at GuggenheimEdwards Lifesciences' (EW) "Buy" Rating Reaffirmed at Guggenheim
www.americanbankingnews.com - February 2 at 4:52 PM
Edwards Lifesciences Corp Expected to Earn FY2022 Earnings of $6.77 Per Share (EW)Edwards Lifesciences Corp Expected to Earn FY2022 Earnings of $6.77 Per Share (EW)
www.americanbankingnews.com - February 2 at 4:32 PM
Edwards Lifesciences (EW) Beats on Q4 Earnings and RevenuesEdwards Lifesciences (EW) Beats on Q4 Earnings and Revenues
finance.yahoo.com - February 2 at 3:24 PM
Mid-Afternoon Market Update: Crude Oil Down 1.5%; Natural Grocers Shares Drop On Earnings MissMid-Afternoon Market Update: Crude Oil Down 1.5%; Natural Grocers Shares Drop On Earnings Miss
feeds.benzinga.com - February 2 at 3:13 PM
Canaccord Genuity Reiterates Buy Rating for Edwards Lifesciences (EW)Canaccord Genuity Reiterates Buy Rating for Edwards Lifesciences (EW)
www.americanbankingnews.com - February 2 at 2:33 PM
Edwards Lifesciences (EW) Receives Buy Rating from Stifel NicolausEdwards Lifesciences (EW) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - February 2 at 12:13 PM
Edwards Lifesciences Reports Fourth Quarter ResultsEdwards Lifesciences Reports Fourth Quarter Results
finance.yahoo.com - February 2 at 6:19 AM
Edwards Beats Fourth-Quarter Views, Issues Bullish Earnings GuideEdwards Beats Fourth-Quarter Views, Issues Bullish Earnings Guide
finance.yahoo.com - February 2 at 6:19 AM
Edwards Lifesciences beats Street 4Q forecastsEdwards Lifesciences beats Street 4Q forecasts
finance.yahoo.com - February 2 at 6:19 AM
Edwards Lifesciences (EW) Announces  Earnings ResultsEdwards Lifesciences (EW) Announces Earnings Results
www.americanbankingnews.com - February 1 at 9:50 PM
Edwards Lifesciences (EW) Releases FY18 Earnings GuidanceEdwards Lifesciences (EW) Releases FY18 Earnings Guidance
www.americanbankingnews.com - February 1 at 5:40 PM
Edwards Lifesciences (EW) Releases Q1 Earnings GuidanceEdwards Lifesciences (EW) Releases Q1 Earnings Guidance
www.americanbankingnews.com - February 1 at 5:40 PM
Edwards Lifesciences Corporation to Host Earnings CallEdwards Lifesciences Corporation to Host Earnings Call
finance.yahoo.com - February 1 at 3:22 PM
Is a Surprise Coming for Edwards Lifesciences (EW) This Earnings Season?Is a Surprise Coming for Edwards Lifesciences (EW) This Earnings Season?
finance.yahoo.com - February 1 at 6:31 AM
Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 5,300 Shares of StockInsider Selling: Edwards Lifesciences Corp (EW) VP Sells 5,300 Shares of Stock
www.americanbankingnews.com - January 31 at 9:26 PM
Edwards Lifesciences Corp (EW) Expected to Announce Earnings of $0.90 Per ShareEdwards Lifesciences Corp (EW) Expected to Announce Earnings of $0.90 Per Share
www.americanbankingnews.com - January 31 at 3:16 AM
Edwards Lifesciences Corp (EW) Receives Average Recommendation of "Buy" from AnalystsEdwards Lifesciences Corp (EW) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 30 at 7:30 PM
Jim Cramer Gives His Opinion On Corning And Medtronic - BenzingaJim Cramer Gives His Opinion On Corning And Medtronic - Benzinga
www.benzinga.com - January 30 at 3:22 PM
Financial Analysis: Edwards Lifesciences (EW) versus Cynosure (CYNO)Financial Analysis: Edwards Lifesciences (EW) versus Cynosure (CYNO)
www.americanbankingnews.com - January 27 at 3:14 PM
Edwards Lifesciences (EW) Scheduled to Post Quarterly Earnings on ThursdayEdwards Lifesciences (EW) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - January 25 at 1:08 AM
Commit To Purchase Edwards Lifesciences Corp At $123, Earn 45.1% Annualized Using Options - NasdaqCommit To Purchase Edwards Lifesciences Corp At $123, Earn 45.1% Annualized Using Options - Nasdaq
www.nasdaq.com - January 22 at 3:27 PM
Edwards Lifesciences' (EW) THVT Likely to Drive Q4 EarningsEdwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings
finance.yahoo.com - January 22 at 3:27 PM
Edwards Lifesciences (EW) THVT Likely to Drive Q4 EarningsEdwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings
www.zacks.com - January 22 at 8:31 AM
[$$] Biomedical Startup Investor Epidarex Capital Plans Expansion[$$] Biomedical Startup Investor Epidarex Capital Plans Expansion
finance.yahoo.com - January 20 at 9:51 AM

SEC Filings

Edwards Lifesciences (NYSE:EW) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Edwards Lifesciences (NYSE:EW) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Edwards Lifesciences (NYSE EW) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.